Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease
Authors not listed
Beau Nakamoto · 2017
Abstract
This is a Phase 1 placebo-controlled biomarker study of NP001 in individuals with Alzheimer's Disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2017). Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease. <em>Beau Nakamoto</em>. https://clinicaltrials.gov/study/NCT03179501
Vancouver
Anonymous. Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease. Beau Nakamoto. 2017.
BibTeX
@misc{anon2017Effect,
title = {Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease},
author = {Anonymous},
journal = {Beau Nakamoto},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Lancet 2021
Preprint · OA
Alzheimer's disease
Handbook of clinical neurology 2019
Citation only
Alzheimer's disease
Nature Reviews Neurology 2024
Preprint · OA
Is Alzheimer disease a disease?
Neuron 2013
Open access · OA
Biomarker Modeling of Alzheimer’s Disease
Nature Medicine 2014
Preprint · OA
Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease
AbbVie 2015
Open access · US-GOV